Publications by authors named "N N Parpieva"
Article Synopsis
- * The LIFT-TB project, involving 7 countries, focused on implementing BPaL under operational research conditions, aiming to assess its feasibility, effectiveness, and safety for selected DR-TB patients.
- * Interim results from November 2020 to March 2023 indicate a high treatment success rate of 90.9% among 574 enrolled patients, with manageable adverse effects and no unexpected complications, demonstrating the
Article Synopsis
- * Despite HCV being a risk factor for liver complications in TB patients, current WHO guidelines do not recommend routine HCV testing during MDR-TB treatment, prompting a study within the TB-PRACTECAL trial to explore co-treatment.
- * Among 552 participants, 4.3% tested positive for HCV, with those on joint treatment showing favorable outcomes, indicating potential benefits in integrating HCV care with MDR-TB management.
Background: Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence of resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components of the all-oral treatment regimen for rifampicin-resistant TB in Uzbekistan.
View Article and Find Full Text PDFBackground: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for INH-resistant, RIF-susceptible TB (HR-TB). Uzbekistan has a high burden of TB (62/100,000 population) and multidrug-resistant TB (12/100,000 population).
View Article and Find Full Text PDFBackground: In 2020, WHO guidelines prioritised the use of a standard fully oral short treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin, ethionamide, ethambutol, high-dose isoniazid, pyrazinamide, and clofazimine for the management of rifampicin-resistant tuberculosis. A high prevalence of resistance to constituent drugs precluded its widespread use by countries in the WHO European region. We evaluated three 9-month fully oral modified STRs (mSTRs) in which ethionamide, ethambutol, isoniazid, and pyrazinamide were replaced by linezolid, cycloserine, or delamanid (or a combination).
View Article and Find Full Text PDF